JP2007277240A5 - - Google Patents

Download PDF

Info

Publication number
JP2007277240A5
JP2007277240A5 JP2007097995A JP2007097995A JP2007277240A5 JP 2007277240 A5 JP2007277240 A5 JP 2007277240A5 JP 2007097995 A JP2007097995 A JP 2007097995A JP 2007097995 A JP2007097995 A JP 2007097995A JP 2007277240 A5 JP2007277240 A5 JP 2007277240A5
Authority
JP
Japan
Prior art keywords
composition according
anticancer
composition
cancer
anticancer agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007097995A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007277240A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2007277240A publication Critical patent/JP2007277240A/ja
Publication of JP2007277240A5 publication Critical patent/JP2007277240A5/ja
Withdrawn legal-status Critical Current

Links

JP2007097995A 2006-04-04 2007-04-04 （２Ｒ，Ｚ）−２−アミノ−２−シクロヘキシル−Ｎ−（５−（１−メチル−１Ｈ−ピラゾール−４−イル）−１−オキソ−２，６−ジヒドロ−１Ｈ−［１，２］ジアゼピノ［４，５，６−ｃｄ］インドール−８−イル）アセトアミドの併用療法 Withdrawn JP2007277240A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78927606P 2006-04-04 2006-04-04

Publications (2)

Publication Number Publication Date
JP2007277240A JP2007277240A (ja) 2007-10-25
JP2007277240A5 true JP2007277240A5 (https=) 2010-05-20

Family

ID=38421777

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007097995A Withdrawn JP2007277240A (ja) 2006-04-04 2007-04-04 （２Ｒ，Ｚ）−２−アミノ−２−シクロヘキシル−Ｎ−（５−（１−メチル−１Ｈ−ピラゾール−４−イル）−１−オキソ−２，６−ジヒドロ−１Ｈ−［１，２］ジアゼピノ［４，５，６−ｃｄ］インドール−８−イル）アセトアミドの併用療法

Country Status (14)

Country Link
US (1) US20090312280A1 (https=)
EP (1) EP2007375A1 (https=)
JP (1) JP2007277240A (https=)
KR (1) KR20080100838A (https=)
CN (1) CN101415417A (https=)
AR (1) AR060284A1 (https=)
AU (1) AU2007232279B2 (https=)
BR (1) BRPI0709731A2 (https=)
CA (1) CA2648371A1 (https=)
IL (1) IL194340A0 (https=)
MX (1) MX2008012791A (https=)
RU (1) RU2409361C2 (https=)
TW (1) TW200806301A (https=)
WO (1) WO2007113671A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2009113436A1 (ja) * 2008-03-14 2011-07-21 国立大学法人 千葉大学 Ｆｇｆｒ３遺伝子阻害剤の放射線照射併用による放射線の抗癌作用増強法および副作用軽減法
KR20100131457A (ko) * 2008-03-27 2010-12-15 다이호야쿠힌고교 가부시키가이샤 시티딘 유도체 및 카르보플라틴을 함유하는 항종양제
US8481557B2 (en) 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
SG10201404012RA (en) * 2009-04-11 2014-09-26 Array Biopharma Inc Checkpoint kinase 1 inhibitors for potentiating dna damaging agents
ES2621857T3 (es) 2010-11-16 2017-07-05 Array Biopharma, Inc. Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1
IN2014DN06169A (https=) 2011-12-31 2015-08-21 Beigene Ltd
MX2014008071A (es) 2011-12-31 2015-07-06 Beigene Ltd Tetra o penta-piridoftalazinonas ciclicas fusionadas como inhibidores de poli(adenosin-difosfato-ribosa)polimerasas.
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
CA2512683C (en) * 2003-01-09 2010-03-16 Pfizer Inc. Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy

Similar Documents

Publication Publication Date Title
JP2007277240A5 (https=)
US11648211B2 (en) Nanoencapsulated combination drug formulations
ES2964764T3 (es) Combinación terapéutica que comprende un inhibidor de cdk y oxaliplatino
CN103282037B (zh) 抗肿瘤生物碱的联合治疗
KR101676062B1 (ko) Ｄｎａ 손상제를 강화시키기 위한 체크포인트 키나제 1 억제제
JP2010520289A5 (https=)
WO2023165603A1 (en) Dna-pk inhibitor and combination use thereof
RU2008139406A (ru) Комдинированная терапия (2r, z)-2-амино-2-циклогексил-n-(1-метил-1н-пиразол-4-ил)-1-оксо-2, 6-дигидо-1н-(1, 2)диазепино(4, 5, 6-d(ндол-8-ил)ацетамидом
CN101743005B (zh) 用7-(2,5-二氢-4-咪唑并[1,2-a]吡啶-3-基-2,5-二氧代-1H-吡咯-3-基)-9-氟-1,2,3,4-四氢-2-(1-哌啶基羰基)-吡咯并[3,2,1-jk][1,4]苯并二氮*增强癌症的化学疗法
JP2010180210A5 (https=)
JP2013542241A5 (https=)
JP2008530248A5 (https=)
JP2011503071A5 (ja) ヨードニトロベンズアミド化合物と抗腫瘍剤の組み合わせによる卵巣がんの治療
CN102753176B (zh) 含有cdc7抑制剂和抗癌药的治疗组合物
JP2011520921A5 (https=)
RU2010151602A (ru) Комбинированная терапия с помощью рм00104 и другого противоопухолевого средства
JP2010532364A5 (https=)
ATE523200T1 (de) Kombination mit sapacitibin (2'-cyano-2'-desoxy- n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosin) und einem zytotoxischen mittel
Dutcher et al. 20th‐Century Advances in Drug Therapy in Oncology—Part II
Hu et al. Current status of CPT and its analogues in the treatment of malignancies
CN116672345A (zh) Parp抑制剂和细胞毒性剂的联合产品及其用途
ES2703739T3 (es) Combinación terapéutica que comprende un inhibidor aurora cinasa y un agente antineoplásico
Raghavendra Camptothecin and analogs: role in anticancer activities
Choy et al. Irinotecan in combined-modality therapy for locally advanced non-small-cell lung cancer
WO2010081825A2 (en) Pirenzepine as an agent in cancer treatment